Omega-3 fatty acid and cardiovascular outcomes: Insights from recent clinical trials
Document Type
Article
Department
Office of the Provost; Cardiology
Abstract
Purpose of review: Omega-3 fatty acids (ω-3 FA) are among the most well-recognized health supplements but their cardiovascular benefits have long been controversial owing to inconsistent results from previous cardiovascular outcomes trials (CVOT). In this article, we provide a short review of existing literature followed by recent randomized clinical trial data, with a discussion of the potential clinical implications of these new findings.
Recent findings: Data from the randomized, controlled trial REDUCE-IT, when viewed within the context of other recently published trials ASCEND and VITAL, add to a growing body of evidence on the use of ω-3 FA therapies in the treatment of atherosclerotic cardiovascular disease (ASCVD). Given the different formulations, dosages, and patient populations studied, CVOTs of ω-3 FA have provided valuable insight into the use of these agents in cardioprotection. Current data suggest that higher dosages of pure eicosapentaenoic acid ω-3 FA formulations provide additional benefit in reduction of ASCVD events.
Publication (Name of Journal)
Current Atherosclerosis Reports
DOI
10.1007/s11883-019-0763-0
Recommended Citation
Jia, X.,
Kohli, P.,
Virani, S. S.
(2019). Omega-3 fatty acid and cardiovascular outcomes: Insights from recent clinical trials. Current Atherosclerosis Reports, 21(1), 1.
Available at:
https://ecommons.aku.edu/provost_office/675
Comments
Pagination is not provided by the author/publisher. This work was published before the author joined Aga Khan University.